NOG-Derived Peptides Can Restore Neuritogenesis on a CRASH Syndrome Cell Model

Area of Science:

• Neuroscience
• Molecular Biology
• Genetics

Background:

• Cell adhesion molecules (CAMs) mediate cell-cell and cell-extracellular matrix interactions via immunoglobulin (Ig)-like repeats.
• L1CAM is vital for neuronal differentiation in developing and mature nervous systems, with Ig2-Ig2 binding implicated in its function.
• L1 diseases, including CRASH neurodevelopmental syndrome, arise from X-linked mutations in the L1CAM gene.

Purpose of the Study:

• To investigate the molecular basis of CRASH phenotypes caused by L1CAM mutations.
• To explore the therapeutic potential of L1CAM-derived peptides in restoring neuronal function.

Main Methods:

• In silico simulations to model the effects of L1CAM mutations (I179S, R184Q) in the Ig2 homophilic binding region.
• Synthesis of a peptide mimicking the L1CAM Ig2 homophilic binding region.
• Testing the peptide's ability to mimic L1CAM's neuritogenic capacity and rescue neuritogenesis in a cellular model of CRASH syndrome.

Main Results:

• In silico simulations elucidated the molecular mechanisms underlying CRASH phenotypes linked to specific L1CAM mutations.
• A synthetic L1CAM peptide replicated the neuritogenic activity of the full L1CAM protein.
• The synthetic peptide effectively rescued neuritogenesis in a cellular model of CRASH syndrome, outperforming the full L1CAM ectodomain.

Conclusions:

• L1CAM mutations I179S and R184Q disrupt homophilic binding, providing a molecular explanation for CRASH syndrome.
• L1CAM-derived peptides demonstrate potential as biotechnological tools and therapeutic agents for L1 diseases.